Mutual Fund Details
NAV
₹161.8820
as on 25 Apr 2025, 11:12 PM
₹-3.2800(1.99%)
Last Change
Download the Paytm Money app now!
Invest in Stocks, F&O, Mutual Funds, IPOs, NFOS and Bonds.
Zero brokerage for 30 days- Zero account opening fees
- Zero AMC for life
Scan QR code to download the app
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,73,015
₹1,77,731
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹77,730
Profit (absolute return)
77.73%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
1.56%
In the last 6 months
2.06%
In the last 1 year
16.51%
In the last 3 years
77.73%
In the last 5 years
184.23%
In the last 10 years
306.62%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Nippon India Pharma Fund Direct-IDCW Reinvestment
as of 31 Mar 2025, 05:30 AM
₹8,080.97 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 1% if redeemed within 1 month.
0.91%
Expense Ratio
Plan
Dividend
Benchmark
BSE Healthcare Total Return Index
Exit Load
Exit load of 1% if redeemed within 1 month.
Scheme Document
Sectors Holding in this Mutual Fund
as on 31 Mar 2025
Healthcare
99.48%
₹8,038.95 Cr
Others
0.52%
₹42.02 Cr
Companies Holding in this Mutual Fund
as on 31 Mar 2025
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,088.51 Cr
Divi's Laboratories Ltd.
8.39%
₹677.99 Cr
Lupin Ltd.
7.67%
₹619.81 Cr
Cipla Ltd.
6.20%
₹501.02 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹488.90 Cr
Others
58.22%
₹4,704.74 Cr
View All
View All
This fund's returns:
21.11%Return Duration
3 Years
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.90%
25.32%
3Y Returns
25.32
SBI Healthcare Opportunities Fund Direct Plan-Growth
EquityPharma
Min. Investment
₹500
Category Returns
15.90%
25.32%
3Y Returns
25.00
Tata India Pharma & HealthCare Fund Direct-Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.90%
25.32%
3Y Returns
22.06
About Nippon India Pharma Fund Direct-IDCW Reinvestment
Nippon India Pharma Fund Direct-IDCW Reinvestment is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date. It has an AUM of ₹8,080.97 Crores and the latest NAV decalared is ₹161.882 as on 27 Apr 2025 at 11:46 pm.
Nippon India Pharma Fund Direct-IDCW Reinvestment scheme return performance in last 1 year is 16.51%, in last 3 years is 77.73% and 686.69% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹8,080.97 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
View AMC Details
₹5,60,218.54 Cr
AUM
271
Schemes
Address
4th Floor, Tower A, Peninsula Business Park,Ganapatrao Kadam Marg, Lower Parel (W),400013
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
